Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis

BACKGROUND AND AIMS: We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs). APPROACH AND RESULTS: In this pooled analysis of two single‐center, phase Ib cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Jun, Sun, Yongkun, Zhang, Wen, Yuan, Jiajia, Peng, Zhi, Wang, Wei, Gong, Jifang, Yang, Lin, Cao, Yanshuo, Zhao, Hong, Chen, Chao, Wang, Weifeng, Shen, Lin, Zhou, Aiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Original Articles: Liver Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9970018/
https://www.ncbi.nlm.nih.gov/pubmed/35491432
http://dx.doi.org/10.1002/hep.32548

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9970018/
https://www.ncbi.nlm.nih.gov/pubmed/35491432
http://dx.doi.org/10.1002/hep.32548

Ejemplares similares